Single center experience of IDH inhibitors in high-grade gliomas

被引：0
|
作者：
Garcia, Catherine R. [1 ]
Highsmith, Kaitlin N. [1 ]
Knight, Stephanie [1 ]
Puduvalli, Vinay K. [1 ]
Kamiya-Matsuoka, Carlos [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14036
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of subclonal IDH mutation status on overall survival in high-grade gliomas
    Vij, M.
    Cobb, W.
    Rashidipour, O.
    Richardson, T.
    Snuderl, M.
    Tsankova, N.
    Walker, J.
    Yokoda, R.
    Yong, R.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 533 - 533
  • [22] High-grade glioma in children and adolescents: a single-center experience
    Yazici, Gozde
    Zorlu, Faruk
    Cengiz, Mustafa
    Ozyigit, Gokhan
    Eren, Gulnihan
    Yuce, Deniz
    Varan, Ali
    Akyuz, Canan
    Akalan, Nejat
    Gurkaynak, Murat
    CHILDS NERVOUS SYSTEM, 2016, 32 (02) : 291 - 297
  • [23] Role of tyrosine kinase inhibitors in the management of high-grade gliomas
    Ahluwalia, Manmeet S.
    Patel, Mital
    Peereboom, David M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (11) : 1739 - 1748
  • [24] Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
    Sahebjam, Solmaz
    Stallworth, Dexter G.
    Mokhtari, Sepideh
    Tran, Nam D.
    Arrington, John A.
    CANCER CONTROL, 2017, 24 (02) : 180 - 186
  • [25] High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.
    Simonelli, Matteo
    Persico, Pasquale
    Dipasquale, Angelo
    Lorenzi, Elena
    Giordano, Laura
    Pessina, Federico
    Navarria, Pierina
    Scorsetti, Marta
    Bello, Lorenzo
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas
    Picca, Alberto
    Touat, Mehdi
    Belin, Lisa
    Gourmelon, Carole
    Harlay, Vincent
    Cuzzubbo, Stefania
    Moyal, Elizabeth Cohen -Jonathan
    Bronnimann, Charlotte
    Stefano, Anna Luisa Di
    Laurent, Isaura
    Lerond, Julie
    Carpentier, Catherine
    Bielle, Franck
    Ducray, Francois
    Dehais, Caroline
    Network, Pola
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [27] MUTATIONAL PROFILING OF HIGH-GRADE GLIOMAS REVEALS INACTIVATING MUTATIONS IN IDH1
    Bleeker, Fonnet E.
    Lamba, Simona
    Zanon, Carlo
    van Tilborg, Angela A.
    Atai, Nadia
    Hulsebos, Theo
    Troost, Dirk
    Leenstra, Sieger
    Vandertop, W. Peter
    van Noorden, Cornelis J.
    Bardelli, Alberto
    NEURO-ONCOLOGY, 2009, 11 (06) : 894 - 894
  • [28] The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
    Juratli, T. A.
    Kirsch, M.
    Geiger, K.
    Klink, B.
    Leipnitz, E.
    Pinzer, T.
    Soucek, S.
    Schrok, E.
    Schackert, G.
    Krex, D.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 110 (03) : 325 - 333
  • [29] Chemotherapy for high-grade gliomas
    Galanis, E
    Buckner, J
    BRITISH JOURNAL OF CANCER, 2000, 82 (08) : 1371 - 1380
  • [30] The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
    T. A. Juratli
    M. Kirsch
    K. Geiger
    B. Klink
    E. Leipnitz
    T. Pinzer
    S. Soucek
    E. Schrok
    G. Schackert
    D. Krex
    Journal of Neuro-Oncology, 2012, 110 : 325 - 333
12345